title: FDA investigation focuses on compounded drugs.
mesh_terms: D000818:Animals; D017277:Drug Approval; D004339:Drug Compounding / Q000662:veterinary*; D004679:Encephalomyelitis / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary; D005334:Fever / Q000139:chemically induced / Q000662:veterinary; D006734:Horse Diseases / Q000139:chemically induced / Q000188:drug therapy; D006736:Horses; D056687:Off-Label Use; D010604:Pharmacy; D011529:Protozoan Infections, Animal / Q000188:drug therapy; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced / Q000662:veterinary; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D014227:Triazines; C036670:toltrazuril; D011739:Pyrimethamine